CTV is a public benefit provided by Veeva Systems to help you find the most relevant clinical trials for you and your loved ones
hormone-receptor (HR) positive and HER2 negative advanced breast cancer, the most common subtype of breast cancer...
Phase 1
London, United Kingdom and 6 other locations
of durvalumab in combination with novel oncology therapies with or without paclitaxel and durvalumab + paclitaxel for first-line metastatic triple...
Phase 1, Phase 2
London, United Kingdom and 31 other locations
The purpose of this study is to find out how effective the combination of crizotinib and fulvestrant is in shrinking lobular breast cancer...
Phase 2
London, United Kingdom and 4 other locations
PHOENIX is a window of opportunity (WOP), open-label, multi-centre, phase IIa trial comprising multiple non-comparative treatment cohorts with patien...
Phase 2
London, United Kingdom and 8 other locations
non-metastatic, high-risk (node positive and/or tumour size ≥ 2cm), triple negative breast cancer. The study aims...
Phase 2
London, United Kingdom
This study will assess the efficacy and safety of Niraparib in participants with either tumor mutation in the BRCA gene (tBRCAmut) HER2- breast...
Phase 3
London, United Kingdom and 199 other locations
This neoadjuvant trial for patients with TNBC and/or gBRCA breast cancer, aims to investigate the safety and efficacy (improvement ...
Phase 2, Phase 3
London, United Kingdom and 29 other locations
levels in combination with chemotherapeutic agents in the first- and second-line treatment of participants with locally advanced/metastatic triple...
Phase 2
London, United Kingdom and 19 other locations
mg twice per day. Capivasertib or placebo could be interrupted for up to 4 weeks for toxicity.Tumor assessments included computed tomograph...
Phase 2
London, United Kingdom and 45 other locations
This is a Phase III, randomised, open-label, 2 arm, multicentre, international study assessing the efficacy and safety of Dato-DXd compared with ICC...
Phase 3
London, United Kingdom and 228 other locations
Clinical trials
Research sites
Resources
Legal